Meet The Professors 2004 VOL 3, ISSUE 3

You are here: Home: Meet The Professors Vol. 3 Issue 3 2005: Case 5: Select publications

Fallowfield LJ. Acceptance of adjuvant endocrine therapies and quality of life issues. Presentation. St Gallens Breast Cancer Conference 2005;S34.

Fumoleau P et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40(4):536-42. Abstract

Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract

Jones SE et al. A retrospective analysis of the proportion of patients responding for ≥1, 1.5 and 2 years in two phase III studies of fulvestrant vs anastrozole. San Antonio Breast Cancer Symposium 2004;Abstract 6047.

Love NH et al. Preferences for oral versus parenteral antitumor therapy: A survey of patients with metastatic breast cancer. Oncology Nursing Society Congress 2005;Abstract 243.

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Paley M et al. Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer. Proc ASCO 2005;Abstract 619.

Robertson JF et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 2004;43(8):529-38. Abstract

Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003;52(4):346-8. Abstract

Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract

Table of Contents

Home

Editor's Note:
Legacy of courage

CASE 1: A 55-year-old woman with a family history of breast cancer diagnosed with a two-centimeter, ER/PR-positive, HER2-negative, Grade II, node-negative invasive ductal carcinoma and Genomic Health recurrence score of 16 (from the practice of Dr Barry D Luskey)

- Select publications

Case 2: A 42-year-old woman presenting with a large, necrotic breast tumor with bilateral pleural effusions, elevated liver function tests and bone metastases and a Grade I, primary ER/PR-positive, HER2-positive invasive carcinoma with lobular features (from the practice of Dr Lance K Lassiter)

- Select publications

Case 3: A 41-year-old woman with a one-centimeter, Grade III, ER/PR-positive, HER2-negative, sentinel node-positive infiltrating ductal carcinoma (IDC) (from the practice of Dr Michael A Schwartz)

- Select publications

Case 4: A 59-year-old woman with a 2.5-centimeter, ER/PR-positive, HER2-positive IDC with 22/29 positive nodes and de novo metastatic disease to the liver, lung and bone (from the practice of Dr Anastas C Provatas)

- Select publications

Case 5: A 55-year-old woman who received adjuvant chemotherapy and tamoxifen for a large, ER/PR-positive, HER2-negative, node-positive tumor with skin involvement presents with multiple skin nodules and extensive osseous metastases six years after local therapy (from the practice of Dr Margaret A Deutsch)

- Select publications

Case 6: A 78-year-old woman originally diagnosed with breast cancer in 1991 and treated with a mastectomy and adjuvant tamoxifen presents with two ERpositive, HER2-negative lesions on her chest wall and axilla and widespread bony metastases (from the practice of Dr Christine H McCarty)

- Select publications

CME Information

Faculty Affiliations; Content Validation and Disclosures;
Medical Oncologist Community Panel

Editor's Office

Home · Contact Us

Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved